The aim. To analyze long-term clinical outcomes of percutaneous coronary intervention (PCI) with bioresorbable vascular scaffold (BVS) Absorb for the treatment of left anterior descending (LAD) lesions. Methods and results. In study were included 87 patients with stable angina and significant (≥70%) LAD disease. The primary end point was target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction and target-vessel revascularization). The secondary end point of major cardiovascular events (MACE) was a composite of death from any cause, all myocardial infarctions, all revascularizations and device thrombosis. Average value SYNTAX score was — 7.46±2.12. Post-dilatation performed in 92% patients. At 12-month rates of target-vessel failure were — 3.45%, target-vessel myocardial infarction — 3.45% and target-vessel revascularization — 2.3%. MACE at 1 year occurred in 6 (6.9%) patients. Rates of death from any cause were 1.14%, all MI — 5.7%, all revascularizations — 4.6% and device thrombosis 2.3%. Conclusions. At 12-month follow up, PCI by BVS Absorb for isolated LAD lesions demonstrates satisfactory results. Despite adherence to the recommendation included in the BVS physician labeling, BVS «Absorb» was associated with a high definite or probable device thrombosis.